Last reviewed · How we verify
NCT06883474
Osteosclerotic Changes on CT Predict Survival in Prostate Cancer
trial testing Osteosclerotic Changes on Computed Tomography in Prostate Cancer (Adenocarcinoma) in 211 participants. Completed in 30 May 2023.
30 May 2023
Quick facts
| Lead sponsor | Sun Yat-sen University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 211 |
| Start date | 1 July 2010 |
| Primary completion | 30 May 2023 |
| Estimated completion | 30 May 2023 |
Drugs / interventions tested
- Osteosclerotic Changes on Computed Tomography
Conditions studied
- Prostate Cancer (Adenocarcinoma) — all drugs for Prostate Cancer (Adenocarcinoma) →
- Prostate Cancer Metastatic Disease — all drugs for Prostate Cancer Metastatic Disease →
Sponsor
Sun Yat-sen University
Who can join
Eligibility, male only, with Prostate Cancer (Adenocarcinoma) or Prostate Cancer Metastatic Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study specifically investigated PC patients with bone metastasis and conducted a comprehensive analysis of the correlation between OCs and patient survival outcomes.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Osteosclerotic changes on computed tomography predict disease progression and poor survival in prostate cancer with osteoblastic metastases.
Chen M, Yang Z, Yang S, Wang J, et al · · 2025 · cited 1× · PMID 40549436 · DOI 10.1097/js9.0000000000002758
Verify or expand the search:
- PubMed search for NCT06883474
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Cancer (Adenocarcinoma)
Currently open trials in the same condition.
- NCT07407608 — ABlative Radiotherapy (for) Unfavorable Prostate Tumors 2.0 · recruiting
- NCT06957691 — Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Pro · Phase 2 · recruiting
- NCT07363382 — The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer · Phase 1, PHASE2 · recruiting
- NCT07302451 — REDI-CaP(Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients) · Phase 2 · active not recruiting
- NCT07115914 — PSMA PET for Surveillance After Focal Therapy · NA · recruiting
Other Sun Yat-sen University trials
Trials by the same sponsor.
- NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
- NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
- NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06883474 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
- Last refreshed: 21 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06883474.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing